Insidious development of pulmonary embolism in asymptomatic patients with COVID-19: Two rare case-reports

Scarce data exist regarding the clinical sequelae of COVID-19 and/or the prevalence of thromboembolic disease in asymptomatic patients. Surely, there is increased prevalence of thromboembolic disease and pulmonary embolism (PE) in critically ill patients with COVID-19; hence the administration of ev...

Full description

Saved in:
Bibliographic Details
Published inRespiratory medicine case reports Vol. 31; p. 101186
Main Authors Alharthy, Abdulrahman, Balhamar, Abdullah, Faqihi, Fahad, Alshaya, Rayan, Noor, AlFateh, Alaklobi, Feisal, Memish, Ziad A., Karakitsos, Dimitrios
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.01.2020
Elsevier
Subjects
Anticoagulation therapy
Asymptomatic disease
Case Report
COVID-19
Deep vein thrombosis
Pulmonary embolism
Thromboinflammation
COVID-19
Pulmonary embolism
Deep vein thrombosis
Anticoagulation therapy
Thromboinflammation
Asymptomatic disease
Online AccessGet full text

Cover

More Information
Summary:Scarce data exist regarding the clinical sequelae of COVID-19 and/or the prevalence of thromboembolic disease in asymptomatic patients. Surely, there is increased prevalence of thromboembolic disease and pulmonary embolism (PE) in critically ill patients with COVID-19; hence the administration of even enhanced thromboprophylaxis was suggested. However, the administration of regular thromboprophylaxis in asymptomatic outpatients is an entirely different matter. Herein, we present the clinical story of insidious PE development in two asymptomatic COVID-19 female patients. Issues regarding the pathogenesis of thromboembolism in COVID-19 and the clinical management are equally discussed.
ISSN:2213-0071
2213-0071
DOI:10.1016/j.rmcr.2020.101186